Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma
Extract o the report: Bortezomib‐containing regimens (BCRs) represented standard, first‐line therapy f...
Read more